The US FDA has issued a Complete Response Letter to Outlook Therapeutics (OTLK) for ONS-5010/Lytenava (bevacizumab-vikg), sending shares plummeting.
Outlook Therapeutics drops 80% on CRL for BLA for wet AMD asset
The US FDA has issued a Complete Response Letter to Outlook Therapeutics (OTLK) for ONS-5010/Lytenava (bevacizumab-vikg), sending shares plummeting.